Table 1 Therapeutic efficacy of FNC in patients with COVID-19. a General outcome of the patient cohort after FNC treatment. b Outcome comparison: known antivirals vs. FNC (a self-controlled comparison). c Outcome comparison after FNC therapy: severe COVID-19 patients vs. those with moderate disease. d Outcome comparison after FNC therapy: FNC plus other antivirals vs. FNC alone

From: Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients

a

       

N = 31

Age

Time from virus-positive to FNC treatment (days)

Time from FNC treatment to SARS-CoV-2 negative conversion (days)

Time from FNC treatment to discharge from the hospital (days)

Duration of FNC treatment (days)

Recovery rate

Side effect

Average

50.19

23.65

3.29

9.00

6.77

100%

(31/31)

16.12%

(5/31)

STDEV

18.90

16.80

2.22

4.93

2.74

Median

51.0

24.0

3.0

9.0

7.0

Range

20–81

3–62

1–9

2–25

2–12

b

     

Treatment

Age

Time from drug treatment to SARS-CoV-2 negative conversion (days)

Time from FNC treatment to discharge from the hospital (days)

Duration of drug treatment (days)

Recovery rate

Drug Rx#, before FNC (n = 11)

53.00 ± 19.75

NA*

NA*

16.36 ± 9.91

0 (0/11)

FNC (n = 11)

53.00 ± 19.75

1.73 ± 0.79

9.09 ± 7.27

6.00 ± 3.03

100% (11/11)

p Value

   

0.0034^

0.0000£

c

       

Severity

Age

Time from virus-positive to FNC treatment (days)

Time from FNC treatment to SARS-CoV-2 negative conversion (days)

Time from FNC treatment to discharge from the hospital (days)

Duration of FNC treatment (days)

Recovery rate

Side effect

Severe

n = 5

50.60 ± 21.05

21.20 ± 14.65

3.00 ± 2.92

5.60 ± 3.78

5.00 ± 3.32

100% (5/5)

40%

(2/5)

Moderate

n = 26

50.12 ± 18.91

24.12 ± 17.41

3.35 ± 2.13

9.65 ± 4.91

7.12 ± 2.55

100% (26/26)

11.5

(3/26)

p Value

0.9592

0.7288

0.7558

0.0922

0.1155

  

d

       

Drug combination

Age

Time from virus-positive to FNC treatment (days)

Time from FNC treatment to SARS-CoV-2 negative conversion (days)

Time from FNC treatment to discharge from the hospital (days)

Duration of FNC treatment (days)

Recovery rate

Side effect

Yes

N = 16

47.56 ± 18.30

17.50 ± 11.89

4.38 ± 2.39

9.31 ± 3.46

7.31 ± 2.85

100%

(16/16)

18.8%

(3/16)

No

N = 15

53.00 ± 19.75

30.20 ± 19.08

2.13 ± 1.30

8.67 ± 6.24

6.20 ± 2.60

100%

(16/16)

13.3%

(2/15)

p Value

0.4327

0.0330

0.0032

0.7219

0.2658

  
  1. @Self-controlled comparison: These 11 patients were first treated with known antivirals; after failure in the early treatment, they were treated with FNC alone
  2. #Drugs: interferon-alpha, arbidol, Lopinavir/ritonavir, chloroquine, ribavirin, or antiviral TCM, with one or more in combination
  3. *Not applicable (no negative conversion, or no discharge from the hospital, after 4–32 days of treatment)
  4. £Chi-square test
  5. ^Unpaired student’s t test
  6. Mean ± SD
  7. P value by unpaired t test
  8. Mean ± SD
  9. P value by unpaired t test
Back to article page